Evidence map›Paper›PMID 32280593›Full record

ArticleUrology case reports2020

Pancreatic metastasis from locally recurrent neuroendocrine differentiated prostate cancer after radical prostatectomy.

Takashi Ando, Kazuhiro Watanabe, Takaki Mizusawa, Takeshi Sakai, Akiyoshi Katagiri

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Takashi AndoDepartment of Urology, Niigata Prefectural Central Hospital, Shinnancho 205, Jouetsushi, Niigata, 943-0192, Japan.
Kazuhiro WatanabeDepartment of Urology, Niigata Prefectural Central Hospital, Shinnancho 205, Jouetsushi, Niigata, 943-0192, Japan.
Takaki MizusawaDepartment of Urology, Niigata Prefectural Central Hospital, Shinnancho 205, Jouetsushi, Niigata, 943-0192, Japan.
Takeshi SakaiDepartment of Pathology, Niigata Prefectural Central Hospital, Shinnancho 205, Jouetsushi, Niigata, 943-0192, Japan.
Akiyoshi KatagiriDepartment of Urology, Niigata Prefectural Central Hospital, Shinnancho 205, Jouetsushi, Niigata, 943-0192, Japan.
Niigata Prefectural Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic metastasis from prostate cancer (PC) is quite rare. Herein, we report the case of a 67-year-old man with pancreatic metastasis from a neuroendocrine differentiated PC (NEDPC), a local recurrence after radical prostatectomy and androgen deprivation therapy for 6 years. Chemoradiotherapy was initiated for the locally recurrent NEDPC, and it had almost disappeared after the therapy. However, rapidly enlarged pancreatic metastasis from the NEDPC was detected 6 months after therapy. There is no standard treatment available for pancreatic metastasis from NEDPC owing to its rarity; hence, further knowledge and clinical experience regarding it are crucial.

Indexed as

ADT, androgen deprivation therapyAndrogen deprivation therapyChemoradiotherapyCT, computed tomographyEUS-guided FNA, Endoscopic ultrasound-guided fine needle aspirationIMRT, intensity-modulated radiation therapyNEDPC, neuroendocrine differentiated prostate cancerNeuroendocrine differentiated prostate cancerNSE, neuron-specific enolasePancreatic metastasisPC, prostate cancerPSA, prostate-specific antigenRP, radical prostatectomy

Identifiers

PMID32280593
PMCPMC7139108
OpenAlexW3014609931

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.